What is Tebentafusp-tebn?

In January 2022, Tebentafusp-tebn was approved for marketing by the U.S. Food and Drug Administration (FDA). It is a bispecific gp100 peptide-HLA-guided CD3 T cell engager and is used for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Efficacy was evaluated inIMCgp100-202, a randomized, open-label, multicenter trial involving 378 patients with metastatic uveal melanoma who were tested centrally Identification of HLA-A*02:01 genotype-positive, previously surgically resected oligometastatic disease was allowed; patients were excluded if they had previously received systemic therapy or local liver-directed therapy or had clinically significant cardiac disease or symptomatic untreated brain metastases. The median overall survival of patients treated with tebenforx was 21.7 months and the progression-free survival was 3.3 months.

The most common adverse reactions) are cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting; The most common laboratory abnormalities (≥50%) are decreased lymphocyte count, increased creatinine, increased glucose, increased aspartate aminotransferase, increased alanine aminotransferase, decreased hemoglobin, and decreased phosphate.

The original drug of Tibenforsi is not currently on the market in China, nor has it been included in medical insurance. After Tebenforx is approved for marketing, there may be less price and other related information. For more drug information and specific prices, please consult a medical consultant.